These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Completed, but no date||2004-003839-31||A Phase III, Multicenter, Open-Label, Long-Term Study of the Tolerability of Intravenous Natalizumab in Crohn's Disease Subjects Who Have Previously Participated in Natalizumab Crohn's Disease Study C...||bad-data|
|Not reported||2004-004120-12||A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, and Amyloid-Imaging Positron Emission Tomography (PET) Trial of AAB-001 (ELN115727) in Patie...||2009-11-12||due-trials|
|Not reported Terminated||2006-004675-35||A Phase II, Multicenter, Open-Label, Long-Term Treatment Study to Determine the Safety, Tolerability and Efficacy of AAB-001 (ELN115727) in Patients with Alzheimer's Disease who Participated in Study ...||2009-05-14||due-trials|
|Reported results||2012-001935-30||A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Safety and Efficacy Study of Oral ELND005 as an Adjunctive Maintenance Treatment in Patients with Bipolar I Disorder||2014-06-09||due-trials|
|Reported results||2012-004299-20||A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's...||2015-05-12||due-trials|
|Reported results||2012-005524-15||A 12-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease. Estudio de extensión de 12 semanas para evaluar l...||2015-08-18||due-trials|